USFDA approves Sun Pharma's psoriasis specialty drug Ilumya
The US-FDA has approved Sun Pharma’s generic Tildrakizumab branded as Ilumya. In an interview to CNBC-Tv18, Deepak Malik of Edelweiss Securities discussed the potential of this.
US Food and Drug Administration has approved Sun Pharma’s generic Tildrakizumab branded as Ilumya.
Deepak Malik of Edelweiss Securities said that Sun Pharma is the first from India to launch this specialty drug in such a big market. "It is not a branded generic but a specialty drug for Sun Pharma."
Malik also expects Ilumya to be launched in the US market in the next six months.
He said that the company was looking to make around USD 200-300 million revenue in the next three-four years. "Sun Pharma is the sixth player entering into the psoriasis market ... It is a $3 billion market and it is a good molecule".
"Have a target of Rs 530 per share for Sun Pharma", he further mentioned.
First Published: Mar 22, 2018 6:47 AM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
BJP is planning to ban RSS, says Shiv Sena (UBT) chief Uddhav Thackeray
May 18, 2024 8:01 PM
Punjab Lok Sabha elections: Complete list of Congress candidates
May 18, 2024 4:08 PM
Punjab Lok Sabha elections: Check full list of AAP candidates and constituencies
May 18, 2024 12:59 PM
PM Modi, Rahul Gandhi election rallies in Delhi today: Here are the routes to avoid
May 18, 2024 11:28 AM